Znaczenie lokalnego układu renina-angiotensyna w patologii gruczołu krokowego

• Authors: Kamila Domińska

Title variants

EN

The importance of the local renin-angiotensin system in the pathology of prostate

• Languages of publication: PL

Abstracts

PL

Wyniki badań in vivo oraz in vitro ujawniły obecność lokalnego układu renina-angiotensyna (RAS) w gruczole krokowym, niemniej jednak rola tego układu zarówno w fizjologii jak i patologii stercza nadal nie jest dobrze znana. Najnowsze doniesienia wskazują, że RAS obok swojej klasycznej roli jest zaangażowany w proliferację, różnicowanie i migrację komórek, angiogenezę, procesy zapalne oraz apoptozę, co sugeruje jego istotny udział w procesie kancerogenezy. Reorganizacja poszczególnych elementów RAS została odnotowana zarówno w łagodnym rozroście jak i nowotworach złośliwych gruczołu krokowego. Powyższe zmiany dotyczyły między innymi, poziomu receptora AT1, ekspresji enzymu konwertującego angiotensynę I jak również lokalnego stężenia angiotensyny II i angiotensynogenu. Niniejsza praca ma na celu podsumowanie dotychczasowej wiedzy odnośnie udziału RAS w zapoczątkowaniu i późniejszym rozwoju raka stercza, jak również przeanalizowanie potencjalnych korzyści wynikających z modulacji RAS w kontekście terapii antynowotworowej.

EN

Results of in vivo and in vitro experiments have demonstrated the presence of a local renin-angiotensin system (RAS) in the prostate. However, the role of this system in the physiology and pathology of the prostate is still unclear. Recent reports have indicated that RAS is also involved in the regulation of cell proliferation, differentiation, migration as well as angiogenesis, inflammation and apoptosis, which suggests its important role in carcinogenesis. Reorganization of individual elements of the renin-angiotensin system has been reported in both benign prostatic hyperplasia and prostate cancer. These changes concerned the expression of AT1 receptor, angiotensin converting enzyme (ACE) and local concentration of angiotensin II or angiotensinogen. This review focuses on the role of RAS in the induction and progression of prostate cancer as well as on the analysis of potential benefits of RAS modulation in anticancer therapy.

Keywords

EN

Benign prostatic hyperplasia; Gruczoł krokowy; Prostate; Prostate cancer; Rak gruczołu krokowego; Renin-angiotensin system; Układ renina-angiotensyna; Łagodny rozrost gruczołu krokowego

Discipline

• MEDICINE: MEDICINE

• Publisher: Łódzkie Towarzystwo Naukowe
• Journal: Folia Medica Lodziensia
• Year: 2009
• Volume: 36
• Issue: 2
• Pages: 73-86

Contributors

author

Kamila Domińska

• Zakład Endokrynologii Porównawczej, Katedra Medycyny, Molekularnej i Biotechnologii, Uniwersytet Medyczny w Łodzi, Polska

References

• Domińska K, Lachowicz-Ochędalska A. Zaangażowanie systemu renina-angiotensyna (RAS) w proces kancerogenezy (The involvement of the renin-angiotensin system (RAS) in cancerogenesis). Postępy Biochem. 2008; 54: 294-300.
• Haulica I, Bild W, Serban DN. Angiotensin peptides and their pleiotropic actions. J Renin Angiotensin Aldosterone Syst 2005; 6: 121-131.
• Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab. 2007; 18:208-214.
• Kwias Z. Rozpoznawanie i leczenie łagodnego rozrostu stercza (The diagnosis and treatment of benign prostate hyperplasia). Przew Lek 2005; 2: 15-23.
• Urban M, Bar K, Starownik R. Choroby rozrostowe gruczołu krokowego (Proliferous diseases of the prostate). Nowa Medycyna 4/2002 (http://www.czytelniamedyczna.pl/nm_cu04.php)
• Dinh DT, Frauman AG, Sourial M i wsp. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology. 2001;142: 1349-1356.
• O'Mahony OA, Barker S, Puddefoot JR I wsp. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology. 2005; 146: 392-398.
• Fabiani ME, Sourial M, Thomas WG i wsp. Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: implications for the pathophysiology of benign prostatic hyperplasia. J Endocrinol. 2001;171: 97-108.
• O'Mahony OA, Barker S, Puddefoot JR i wsp. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology. 2005; 146: 392-398.
• Uemura H, Ishiguro H, Kubota Y. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer.Mini Rev Med Chem. 2006; 6: 835-844.
• Leung PS, Sernia C. The renin-angiotensin system and male reproduction: new functions for old hormones.J Mol Endocrinol. 2003; 30: 263-270.
• Nassis L, Frauman AG, Ohishi M i wsp. Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Pathol. 2001; 195: 571-579.
• Dinh DT, Frauman AG, Casley DJ i wsp. Angiotensin AT(4) receptors in the normal human and benign prostatic hyperplasia. Mol Cell Endocrinol. 2001; 184:187-192.
• Chow L, Rezmann L, Catt KJ I wsp. Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol. 2009; 302: 219-229.
• Louis SN, Wang L, Chow L i wsp. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate. Cancer Detect. Prev. 2007; 31: 391–395.
• Dinh DT, Frauman AG, Somers GR i wsp. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol. 2002; 196: 213-219.
• Baiardi G, Macova M, Armando I i wsp. Estrogen upregulates renal angiotensin II AT1 and AT2 receptors in the rat. Regul Pept. 2005; 124: 7–17.
• Leung PS, Wong TP, Chung YW i wsp. Androgen dependent expression of AT1 receptor and its regulation of anion secretion in rat epididymis. Cell Biol Int. 2002; 26: 117–122.
• Uemura H, Hasumi H, Ishiguro H i wsp. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate. 2006; 66:822-830.
• Uemura H, Ishiguro H, Nakaigawa N i wsp. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003; 2: 1139-1147.
• Stone KR, Mickey DD, Wunderli H i wsp. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978 Mar 15;21:274-281.
• Chow L, Rezmann L, Imamura K i wsp. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate. 2008; 68: 651-660.
• Lin J, Freeman MR. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 2003; 54: 1–7.
• Sidorkiewicz M, Rębas E, Szymajda M i wsp. Angiotensin receptors in hormone-independent prostate cancer cell line DU145: presence of two variants of angiotensin type 1 receptor. Med Sci Monit. 2009; 15: 106-110.
• Ławnicka H, Potocka AM, Juzala A i wsp. Angiotensin II and its fragments (angiotensins III and IV) decrease the growth of DU-145 prostate cancer in vitro.Med Sci Monit. 2004; 10: 410-413.
• Teranishi J, Ishiguro H, Hoshino K i wsp. Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells. Prostate 2008; 68: 1666-1673.
• Domińska K, Piastowska AW, Rębas E i wsp. The influence of peptides from angiotensin family on tyrosine kinase activity and cell viability in human hormonedependent prostate cancer line. Endokrynologia Polska 2009; 5: 363-369.
• Medeiros R, Vasconcelos A, Costa S i wsp. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer J Pathol. 2004; 202: 330-335.
• Yigit B, Bozkurt N, Narter F i wsp. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res. 2007; 27: 933-936.
• van der Knaap R, Siemes C, Coebergh JW i wsp. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008; 112: 748-757.
• Lemiński A, Bińczak-Kuleta A, Kaczmarczyk M i wsp. Polimorfizm i/d genu konwertazy angiotensyny I u chorych na raka gruczołu krokowego. Urologia Polska 2008; 61(Supl.1)
• Uemura H, Ishiguro H, Ishiguro Y, Hoshino K, Takahashi S, Kubota Y. Angiotensin II induces oxidative stress in prostate cancer. Mol Cancer Res. 2008;6:250-258.
• Ino K, Shibata K, Kajiyama H i wsp. Manipulating the angiotensin system — new approaches to the treatment of solid tumours. Expert Opin Biol Ther 2006; 6: 243-255.
• Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293-299.
• Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol. 2008, 15: 19-26.
• Uemura H, Hasumi H, Kawahara T i wsp. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 2005;10:405-10.
• Uemura H, Ishiguro H, Kubota Y. Molecular targeting therapy with angiotensin II receptor blocker for prostate cancer. Oncol. Rev 2007,1: 3-13.
• Ronquist G, Rodríguez LA, Ruigómez A i wsp. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004 Jan 1;58: 50-56.
• Ronquist G, Frithz G, Wang YH i wsp. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer Scand J Urol Nephrol. 2009; 43 :32-36.
• Funao K, Matsuyama M, Kawahito Y i wsp. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep. 2008; 20: 295-300.
• Uemura H, Ishiguro H, Nagashima Y i wsp. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther. 2005, 4: 1699-1709.
• Yu W, Zhao YY, Zhao ZW i wsp. Angiotension II receptor 1 blocker modifies the expression of apoptosis-related proteins and transforming growth factor-beta1 in prostate tissue of spontaneously hypertensive rats. BJU Int. 2007; 100: 1161-1165.
• Perron L, Bairati I, Harel F i wsp. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004; 15: 535-541.
• Filipiak KJ, Niewada M. Efekt klasy a inhibitory konwertazy angiotensyny (Class effect and angiotensin-converting enzyme inhibitors). Polski Przegląd Kardiologiczny 2001; 4: 329-336.
• Sica DA, Ichihara A. The Renin Report. J Renin Angiotensin Aldosterone Syst. 2006; 7: 247-251.
• Domińska K. Genetic changes observed in prostate cancer. The Central European Journal of Urology 2009; 62: 4-8.

• Document Type: paper